Loading…
Verrica Pharmaceuticals Inc. is projected to decline to $5.88 by 2027, a -3% move from its current price of $6.06. VRCA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $5.78 | $6.06 | $6.35 | -0.03% |
| May 30 | $5.66 | $6.06 | $6.48 | -0.06% |
| May 31 | $5.58 | $6.05 | $6.57 | -0.09% |
| Jun 1 | $5.51 | $6.05 | $6.65 | -0.11% |
| Jun 2 | $5.44 | $6.05 | $6.73 | -0.14% |
| Jun 3 | $5.39 | $6.05 | $6.79 | -0.17% |
| Jun 4 | $5.34 | $6.05 | $6.86 | -0.20% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.34 | $6.05 | $6.86 | -0.20% |
| Week 2 | $5.06 | $6.04 | $7.21 | -0.40% |
| Week 3 | $4.85 | $6.02 | $7.48 | -0.60% |
| Week 4 | $4.68 | $6.01 | $7.72 | -0.80% |
| Week 5 | $4.53 | $6.00 | $7.94 | -1.00% |
| Week 6 | $4.40 | $5.99 | $8.14 | -1.20% |
| Week 7 | $4.29 | $5.98 | $8.33 | -1.40% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company that develops and commercializes medications for the treatment of dermatologic diseases in the United States. It offers YCANTH (VP-102), a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts.
VP-315 is an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. Verrica has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications.
Verrica Pharmaceuticals was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
VRCA is currently priced at $6.06 per share, with a market capitalization of $104.1M. It ranks 4212 in the market by this size. The near-term technical picture remains neutral, with a 30-day range from $4.35 to $8.45 and a current price near key moving averages.
The 30-day range and the current price should be weighed against a broader forecast that projects mixed to bullish long-run outcomes, with 2026 averaging $6.06 and 2050 averaging $16.39, along with a 2050 potential max of $37.70 and an ROI of 170.5% in that year. These are estimates, not guarantees, and not financial advice.
A major floor 36.4% below — a decisive break under it would weaken the trend.
The nearest floor, 7.8% below — buyers have tended to step in here.
The nearest ceiling, 39.1% above — a clean break opens room to run.
A major ceiling 57.3% above — clearing it would confirm fresh momentum.
Key VRCA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VRCA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.01 | Buy | $6.06 | Buy |
| MA 10 | $6.21 | Sell | $6.24 | Sell |
| MA 20 | $6.70 | Sell | $6.41 | Sell |
| MA 50 | $6.11 | Sell | $6.34 | Sell |
| MA 100 | $6.40 | Sell | $6.27 | Sell |
| MA 200 | $5.91 | Buy | $6.95 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.22 | Neutral |
| Stoch RSI (14) | 19.33 | Buy |
| CCI (20) | -60.67 | Neutral |
| Williams %R (14) | -82.26 | Info |
| MACD (12,26,9) | -0.16 | Sell |
| ROC (12) | -24.16 | Sell |
| Bollinger %B (20,2) | 0.30 | Neutral |
| Stochastic %K (14) | 17.74 | Buy |
| TRIX (15) | 0.18 | Buy |
| Awesome (5,34) | -0.48 | Sell |
| Ultimate (7,14,28) | 37.47 | Neutral |
| Momentum (10) | -1.09 | Sell |
| Aroon Osc (25) | -36.00 | Sell |
| Hull MA (9) | 5.99 | Buy |
| ADX (14) | 16.76 | Neutral |
| ATR (14) | 0.28 | Info |
The near-term technical picture is NEUTRAL with RSI14 at 50. The stock is trading around the 50-day moving average, with the SMA50 at $6.11 and the SMA200 at $5.91. Support is identified at $5.59 and resistance at $8.43, framing a 30-day price range of $4.35 to $8.45.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.38 | $6.06 | $8.44 | 0% | Neutral | |
| $4.33 | $5.88 | $8.61 | -3% | Neutral | |
| $4.16 | $5.95 | $9.21 | -2% | Neutral | |
| $3.67 | $5.48 | $8.86 | -10% | Neutral | |
| $3.37 | $5.24 | $8.79 | -14% | Neutral | |
| $4.15 | $6.69 | $11.58 | +10% | Neutral | |
| $4.83 | $8.07 | $14.37 | +33% | Bullish | |
| $4.89 | $8.44 | $15.41 | +39% | Bullish | |
| $4.48 | $7.99 | $14.93 | +32% | Bullish | |
| $4.29 | $7.91 | $15.09 | +31% | Bullish | |
| $5.44 | $11.65 | $24.27 | +92% | Bullish | |
| $7.59 | $16.87 | $38.80 | +178% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $4.38 | $6.06 | $7.21 | +0.00% |
| June 2026 | $5.09 | $6.08 | $7.49 | +0.26% |
| July 2026 | $4.87 | $5.90 | $7.45 | -2.83% |
| August 2026 | $4.98 | $6.10 | $7.83 | +3.31% |
| September 2026 | $5.03 | $6.22 | $8.10 | +2.04% |
| October 2026 | $4.77 | $5.96 | $7.86 | -4.25% |
| November 2026 | $4.70 | $5.92 | $7.89 | -0.68% |
| December 2026 | $4.94 | $6.27 | $8.44 | +5.94% |
Click any year to see its month-by-month VRCA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The VRCA price prediction for 2026 points to an average of $6.06 (low $4.38, high $8.44) — a potential gain of 0% on today's $6.06. A consolidation phase looks the most probable path here.
In 2027, VRCA is projected to trade between $4.33 and $8.61, averaging $5.88 — a potential decline of -3% from today's $6.06. That is -3% versus the projected 2026 average. Price action looks broadly range-bound.
Verrica Pharmaceuticals Inc.'s 2028 outlook centres on $5.95, within a $4.16 to $9.21 range. That is up +1% on the projected 2027 average. That marks a -2% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, VRCA could reach as high as $8.86, with a base case around $5.48 and support toward $3.67 — roughly -10% from $6.06. Price action looks broadly range-bound.
Expect VRCA to range from $3.37 to $8.79 through 2030. The $5.24 average target implies a -14% move from current prices. That is -4% versus the projected 2029 average. A consolidation phase looks the most probable path here.
The VRCA price prediction for 2031 points to an average of $6.69 (low $4.15, high $11.58) — a potential gain of +10% on today's $6.06. Price action looks broadly range-bound.
In 2032, VRCA is projected to trade between $4.83 and $14.37, averaging $8.07 — a potential gain of +33% from today's $6.06. That is up +21% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Verrica Pharmaceuticals Inc.'s 2033 outlook centres on $8.44, within a $4.89 to $15.41 range. That is up +5% on the projected 2032 average. That marks a +39% change versus current levels. Momentum favours further upside here.
By 2034, VRCA could reach as high as $14.93, with a base case around $7.99 and support toward $4.48 — roughly +32% from $6.06. Buyers look set to stay in control over this stretch.
Expect VRCA to range from $4.29 to $15.09 through 2035. The $7.91 average target implies a +31% move from current prices. That is -1% versus the projected 2034 average. Momentum favours further upside here.
The VRCA price prediction for 2040 points to an average of $11.65 (low $5.44, high $24.27) — a potential gain of +92% on today's $6.06. Buyers look set to stay in control over this stretch.
In 2050, VRCA is projected to trade between $7.59 and $38.80, averaging $16.87 — a potential gain of +178% from today's $6.06. That is up +45% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in VRCA today (≈ 165.016502 VRCA) could be worth
$2,783.85
+$1,783.85 (+178%) by 2050 · US Dollar
Based on the average projected VRCA price of $16.87 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VRCAwould be worth at today's price.
$1,000 invested in VRCA on May 27, 2025 (≈ 174.520069 VRCA) would be worth
$1,057.59
+$57.59 (+5.8%) today · 1.06× · US Dollar
Based on a VRCA entry price of $5.73 vs. today's $6.06.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.02 | $1,006.64 | +0.7% |
| 1 month ago | $6.82 | $887.91 | -11.2% |
| 3 months ago | $5.47 | $1,107.86 | +10.8% |
| 6 months ago | $9.1 | $665.93 | -33.4% |
| 1 year ago | $5.73 | $1,057.59 | +5.8% |
| All time (5.0y) ago | $103 | $58.83 | -94.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VRCA forecast.
Our base-case forecast reaches $12.00 around 2050.
Implied market cap at $12.00: $206.15M
The multi-year forecast shows a bearish period in 2030 (min $3.15, avg $5.01, max $8.57) with a -17.4% ROI. Sentiment then shifts to NEUTRAL in 2031, before turning BULLISH from 2032 onward, with 2032 averaging $7.99 and a max of $14.55 (ROI 31.9%). The trajectory remains bullish through 2033 ($8.23 avg, max $15.36, ROI 35.7%), 2034 ($7.91 avg, max $15.13, ROI 30.5%), and 2035 ($7.78 avg, max $15.21, ROI 28.4%).
By 2040, the forecast shows an average of $11.47 with a max of $24.56 and a strong 89.3% ROI, continuing into 2050 with an average of $16.39, a max of $37.70, and a 170.5% ROI, all under a BULLISH sentiment. These are estimates, not guarantees, and not financial advice.
Tap a question to reveal the answer.
The 2030 forecast shows min $3.15, avg $5.01, max $8.57 with ROI -17.4% and bearish sentiment.
Long-run forecasts suggest bullish potential from 2032 onward, with 2032 avg $7.99, 2033 avg $8.23, 2040 avg $11.47 and 2050 avg $16.39; ROI reaches up to 170.5% by 2050, but earlier years show declines and uncertainty.
The 2032 max is $14.55, which exceeds $10, while the 2032 average is $7.99.
Current price is $6.06 and market cap is $104.1M.
Bullish sentiment appears from 2032 onward (2032, 2033, 2034, 2035), and continues in 2040 and 2050.
Verrica Pharmaceuticals Inc. Community Discussion
0Share your Verrica Pharmaceuticals Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.